On Tuesday, Shares of Delta Air Lines, Inc. (NYSE:DAL), lost -2.57% to $43.21.
Delta Air Lines, stated financial and operating performance for May 2015.
Merged passenger unit revenue (PRASM) for the month of May reduced 5.5 percent year over year, with roughly half of the decline due to foreign exchange pressure and lower surcharges in international markets and the remainder from lower domestic yields. Delta now anticipates merged PRASM for the June quarter to decline about 4 to 5 percent, with the change from previous guidance a result of lower-than-predictable close-in domestic business yields.
Delta Air Lines, Inc. provides planned air transportation for passengers and cargo worldwide. The company operates in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.
Shares of Merck & Co. Inc. (NYSE:MRK), declined -0.84% to $60.24, during its last trading session.
Merck & Co., known as MSD outside the United States and Canada, recently declared that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-containing chemotherapy and an FDA-approved therapy for EGFR or ALK genomic tumor aberrations, if present. The FDA granted Priority Review with a PDUFA, or target action, date of October 2, 2015; the sBLA will be reviewed under the FDA’s Accelerated Approval program.
The sBLA submission was based in part on data from KEYNOTE-001 – counting patients with greater than or equal to 50 percent of tumor cells positive for PD-L1 expression – which were presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting. These data also served as the basis for the FDA Breakthrough Therapy designation for KEYTRUDA in advanced NSCLC. Merck has filed for approval of KEYTRUDA monotherapy at a dose of 2 mg/kg every three weeks, which is the presently approved dose for advanced melanoma.
As formerly declared, a Premarket Approval Application (PMA) was presented by Dako North America, Inc., an Agilent Technologies Company, for an immunohistochemistry companion diagnostic test that detects PD-L1 expression, PD-L1 IHC 22C3 PharmDx™.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
At the end of Tuesday’s trade, Shares of Occidental Petroleum Corporation (NYSE:OXY), gained 0.70% to $79.44, as Oil prices rose to the highest level of the year Tuesday on a weaker dollar and expectations of a fifth straight weekly decline in U.S. crude supplies.
Crude oil for July delivery settled $1.06 higher at $61.26 per barrel while July natural gas futures rose 5 cents to finish at $2.70 per 1 million BTU.
Occidental Petroleum Corporation engages in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates in three segments: Oil and Gas; Chemical; and Midstream, Marketing and Other.
Finally, UnitedHealth Group Incorporated (NYSE:UNH), ended its last trade with -1.76% loss, and closed at $117.75.
UnitedHealth Group Incorporated, declared that its Board of Directors authorized payment of a cash dividend of $0.50 per share, to be paid on June 24, 2015, to all shareholders of record of UnitedHealth Group common stock as of the close of business on June 15, 2015. This dividend represents a 33 percent enhance over the quarterly dividend of $0.375 per share the Company has been paying since the second quarter of 2014. Future dividend payments are subject to Board approval and may be adjusted as business needs or market conditions change.
David S. Wichmann, president and chief financial officer, UnitedHealth Group, said, “We entered 2015 with strong momentum and expect to continue to grow and diversify throughout the year, into 2016 and beyond. Our growth is grounded in our drive to perform better every day on behalf of the people we are privileged to serve while ongoing to improve the health care system itself. The strength and consistency of that growth is reflected in our raised dividend to shareholders.”
UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
